AB0482 Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registry

Abstract

BackgroundThe aim of this study was to investigate the drug survival, its efficacy and safety in patients withRA based on the database from the Turkish TURKBIO registryMethodsA total of 180 patients were treated with TOFA forRA. Drug survival was assessed. In 118 patients with available data, treatment response was evaluated using thenumber of sensitive and swollen joints, VAS values, DAS28, HAQ and CRPat weeks 12,24,48 and 60ResultsAt baseline, RA patients had a median(Q1-Q3)disease duration of 14 years.75 patients had used ≥1 biologics previously. The other demographic and clinical features of the patients were shown in table 1. Median(Q1-Q3)followup period was137 weeks. After48 and137 weeks,75% and 48%of the patients respectively, maintained TOFA (figure 1). The most common reason for drug discontinuation was ineffectiveness of treatment(63%), followed by adverse events (23%). After 12 weeks, all disease activity parameters were reduced significantly compared to the baseline and most of them continued to be reduced until week60. No difference was observed in disease activity parameters between the groups with and without previous ≥1biologics at weeks 0,12 and 24 (table 2) Remission rate was(43%)at week 60(observed data) (table 2) A total of 9 adverse events(3infection,3allergic rx,2 rash)were observed during the followup periodConclusionsTreatment with TOFA may provide good response rates in RA patients refractory previous biologicalsDisclosure of InterestNone declaredAbstract AB0482 – Table 1Week 0Week 12Week 24Week 36Week 48Week 60*p**P***p Patients with response data, (n)1183941313228Disease activity level, n (%)Remission7 (6)17 (47)10 (32)16 (59)12 (43)17 (63)Moderate64 (59)14 (39)12 (39)7 (26)10 (36)8 (30)High29 (27)1 (3)1 (3)1 (4)2 (7)2 (7)DAS28, Median (Q1-Q3)4.4 (3.7–5.1)2.8(2–3.5)3(2.4–3.6)2.2(1.9–3.3)3.1(1.9–4.2)2.1(1.9–4.1)< 0.001< 0.001< 0.001Swollen joint (0–28); Median(Q1-Q3)2 (0–4.3)00000< 0.001< 0.001< 0.001Tender joint (0–28); Median (Q1-Q3)4 (2–10)0 (0–1.3)0 (0–2)0 (0–0)0 (0–2)0 (0–0)< 0.001< 0.001< 0.001CRP (mg/L); Median (Q1-Q3)13 (4.7–29)4.8 (3–12.8)4.3 (3–10.3)4 (3–9)6 (3–12)9 (3–17.5)0.0050.0150.110Patient global score (0–100); Median62.5 (42–80)44 (12–60)30 (20 – 50)27(12–31)30.5 (15–69)27.5 (13–46)< 0.0010.001< 0.001HAQ score; Median1 (0.8–1.5)0.5 (0–1.3)0.6 (0.1–1.3)0.5 (0.3–0.8)0.6 (0.2–1.2)0.6 (0–1)0.0030.0080.001Abstract AB0482 – Table 2Disease activity parameters baseline and weeks12,24,36,48 and 60First biological tofacitinib n:105 Response data:n 581815 DAS28, Median 4.5 (3.7–5.2)2.4 (1.6 3.6)3 (2.4–3.6) (Das 28<3.1) n 11 (19%)11 (61%)8 (53%) Using other biological drugs before TOFA n:75 response data, n 501816 DAS28, Median4.4 (3.7–5)2.9 (2.4 3.5)3 (2.3–3.7) Das28<3.1 n (%) 4 (8%)10 (56%)10 (63%) #p 0.577 0.516 0.921 ##p 0.173 1.000 0.879 *p for week 0 vs 12; **p for week 0 vs 48,***p for week 0 vs 60 #p das28median for TOFA versus other biologial ##p das28 <3.1for TOFAversus other biological

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

“…Analysis of the Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM-RA) Registry found that drug maintenance in tofacitinib initiators (n = 806) was significantly higher than TNFi initiators (n = 1862) and comparable with non-TNFi bDMARDs (eg, rituximab, tocilizumab, abatacept) initiators (n = 1355). Median (IQR) drug maintenance was 25 months (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) 1.24) for both non-TNFi bDMARDs and tofacitinib. Discontinuation was most commonly due to ineffectiveness with lower rates for tofacitinib (46%) compared with non-TNFi bDMARDs (50%) and TNFi (57%).…”

<p>Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review</p>

“…Study characteristics are described in Supplementary Table 6. 28 studies were performed in patients with IA; 18,19,26-28,30-36,47,49-51,55-57, 59-63,67,79,80,83 25 in patients with RA; 7,16,17,23,24,37,39,40,[42][43][44][45]53,54,58,66,68,70,[73][74][75][76][77][78]84 5 in patients with AS; 21,25,46,48,65 4 in patients with PsA; 41,64,71,81 4 in patients with UC; 22,69,72,82 2 in patients with IBD (with results reported separately for UC); 38,52 and one in patients with SpA. 29 Most studies were retrospective (n=37), while 28 were prospective and one was cross-sectional.…”

“…Among the studies including patients with IA, 21 studies included some form of PRO, 18,20,21,23,24,27,[29][30][31]36,48,49,54,57,59,65,75,77,78,80,84 of which 10 studies reported PROs prior to the switch only and therefore did not provide any information on the patient experience of switching treatment. 20,21,23,24,[29][30][31]49,59,78 The PRO measurement tools used are summarized in Figure 3.…”

“…20,21,23,24,[29][30][31]49,59,78 The PRO measurement tools used are summarized in Figure 3. The most commonly used tool was the Health Assessment Questionnaire (HAQ) (12 studies), 18,20,23,24,31,48,49,54,65,75,77,84 while the least common measurement methods were Routine Assessment of Patient Index Data 3 (RAPID3) and Treatment Satisfaction Questionnaire for Medication (TSQM), each of which were used in one study only. 48 No study on patients with UC presented data on PROs before or after treatment switch.…”

“…Zengin 2018 reported a statistically significant decrease in mean PGA score at week 60 compared to baseline. 84…”